{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T09:11:18Z","timestamp":1791191478885,"version":"4.1.0"},"publisher-location":"Chichester, UK","reference-count":44,"publisher":"John Wiley & Sons, Ltd","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1002\/14651858.cd009043.pub2","type":"reference-entry","created":{"date-parts":[[2012,5,10]],"date-time":"2012-05-10T20:25:40Z","timestamp":1336681540000},"source":"Crossref","is-referenced-by-count":59,"title":["Aripiprazole for autism spectrum disorders (ASD)"],"prefix":"10.1002","author":[{"given":"Heidi","family":"Ching","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Pringsheim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,5,16]]},"reference":[{"issue":"11","key":"10.1002\/14651858.CD009043.pub2-BIB1|cit1","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1097\/CHI.0b013e3181b76658","article-title":"A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder","volume":"48","author":"Marcus","year":"2009","journal-title":"Journal of the American Academy of Child and Adolescent Psychiatry"},{"issue":"6","key":"10.1002\/14651858.CD009043.pub2-BIB2|cit2","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1542\/peds.2008-3782","article-title":"Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder","volume":"124","author":"Owen","year":"2009","journal-title":"Pediatrics"},{"issue":"5","key":"10.1002\/14651858.CD009043.pub2-BIB3|cit3","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1089\/cap.2009.0120","article-title":"Line item analysis of the Aberrant Behaviour Checklist: results from two studies of aripiprazole in the treatment of irritability associated with autistic disorder","volume":"20","author":"Aman","year":"2010","journal-title":"Journal of Child and Adolescent Psychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD009043.pub2-BIB4|cit4","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s11920-010-0172-0","article-title":"Aripiprazole to treat irritability associated with autism: a placebo-controlled, fixed-dose trial","volume":"13","author":"Benton","year":"2011","journal-title":"Current Psychiatry Reports"},{"issue":"4","key":"10.1002\/14651858.CD009043.pub2-BIB5|cit5","doi-asserted-by":"crossref","first-page":"375","DOI":"10.2217\/phe.10.45","article-title":"Aripiprazole for irritability associated with autistic disorder in children and adolescents aged 6-17 years","volume":"4","author":"Blankenship","year":"2010","journal-title":"Pediatric Health"},{"issue":"3","key":"10.1002\/14651858.CD009043.pub2-BIB6|cit6","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.nurt.2010.04.001","article-title":"Aripiprazole in autism spectrum disorders and fragile X syndrome","volume":"7","author":"Erickson","year":"2010","journal-title":"Neurotherapeutics"},{"issue":"4","key":"10.1002\/14651858.CD009043.pub2-BIB7|cit7","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1517\/14656566.2011.557661","article-title":"Aripiprazole for the treatment of irritability associated with autism","volume":"12","author":"Farmer","year":"2011","journal-title":"Expert Opinion on Pharmacotherapy"},{"issue":"2","key":"10.1002\/14651858.CD009043.pub2-BIB8|cit8","first-page":"211","article-title":"Aripiprazole improves social interaction in Taiwanese children with pervasive developmental disorder","volume":"33","author":"Huang","year":"2010","journal-title":"Chang Gung Medical Journal"},{"issue":"11Suppl3","key":"10.1002\/14651858.CD009043.pub2-BIB9|cit9","first-page":"A428","article-title":"Efficacy and safety of aripiprazole for the treatment of irritability associated with autistic disorder in children and adolescents (6-17 years): results from two 8-week, randomized, double-blind, placebo controlled trials","volume":"72","author":"Lewis","year":"2009","journal-title":"Neurology"},{"issue":"6","key":"10.1002\/14651858.CD009043.pub2-BIB10|cit10","doi-asserted-by":"crossref","first-page":"511","DOI":"10.2165\/00023210-200923060-00005","article-title":"Aripiprazole monotherapy in children and young adolescents with pervasive developmental disorders: a retrospective study","volume":"23","author":"Masi","year":"2009","journal-title":"CNS Drugs"},{"key":"10.1002\/14651858.CD009043.pub2-BIB11|cit11","first-page":"S259","article-title":"An open label trial of aripiprazole in the treatment of autism and its correlation to whole blood serotonin levels and serotonin transporter (5HTTPLR) function","volume":"31","author":"Narasimhan","year":"2006","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD009043.pub2-BIB12|cit12","first-page":"e1","article-title":"Safety and tolerability of aripiprazole in the treatment of irritability associated with autistic disorder in pediatric subjects (6-17 years): results from a pooled analysis of 2 studies","volume":"13","author":"Robb","year":"2011","journal-title":"Primary Care Companion to the Journal of Clinical Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD009043.pub2-BIB13|cit13","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1089\/cap.2004.14.455","article-title":"Aripiprazole for maladaptive behaviour in pervasive developmental disorders","volume":"14","author":"Stigler","year":"2004","journal-title":"Journal of Child and Adolescent Psychopharmacology"},{"key":"10.1002\/14651858.CD009043.pub2-BIB14|cit14","first-page":"S194","article-title":"A prospective open label study of aripiprazole in youth with Asperger's disorder and pervasive developmental disorder not otherwise specified","volume":"31","author":"Stigler","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD009043.pub2-BIB15|cit15","volume-title":"Aberrant Behaviour Checklist: Manual","author":"Aman","year":"1986"},{"key":"10.1002\/14651858.CD009043.pub2-BIB16|cit16","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/BF02211843","article-title":"The effects of haloperidol on discrimination learning and behavioural symptoms in autistic children","volume":"19","author":"Anderson","year":"1989","journal-title":"Journal of Autism and Developmental Disorders"},{"key":"10.1002\/14651858.CD009043.pub2-BIB17|cit17","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","year":"2000"},{"issue":"6","key":"10.1002\/14651858.CD009043.pub2-BIB18|cit18","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1192\/bjp.bp.108.059345","article-title":"Prevalence of autism spectrum conditions: UK school based population study","volume":"194","author":"Baron-Cohen","year":"2009","journal-title":"British Journal of Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD009043.pub2-BIB19|cit19","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/BF01531306","article-title":"The effects of haloperidol on learning and behaviour in autistic children","volume":"12","author":"Campbell","year":"1982","journal-title":"Journal of Autism and Developmental Disorders"},{"issue":"6","key":"10.1002\/14651858.CD009043.pub2-BIB20|cit20","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1097\/00004583-199706000-00022","article-title":"Neuroleptic-related dyskinesias in autistic children: a prospective, longitudinal study","volume":"36","author":"Campbell","year":"1997","journal-title":"Journal of the American Academy of Child and Adolescent Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD009043.pub2-BIB21|cit21","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analysis involving cross-over trials: methodological issues","volume":"31","author":"Elbourne","year":"2002","journal-title":"International Journal of Epidemiology"},{"key":"10.1002\/14651858.CD009043.pub2-BIB22|cit22","unstructured":"Label and approval history: ability www.accessdata.fda.gov\/scripts\/cder\/drugsatfda\/index.cfm?fuseraction=Search.Label_ApprovalHistory#apphist"},{"issue":"11","key":"10.1002\/14651858.CD009043.pub2-BIB23|cit23","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1176\/appi.ajp.2008.07061035","article-title":"A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia","volume":"165","author":"Findling","year":"2008","journal-title":"American Journal of Psychiatry"},{"issue":"10","key":"10.1002\/14651858.CD009043.pub2-BIB24|cit24","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.4088\/JCP.09m05164yel","article-title":"Acute treatment of pediatric bipolar I disorder, manic or mixed episode, with aripiprazole: a randomized, double-blind, placebo-controlled study","volume":"70","author":"Findling","year":"2009","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD009043.pub2-BIB25|cit25","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1001\/archpsyc.1989.01810110048007","article-title":"The Yale-Brown Obsessive Compulsive Scale. I. Development, Use, and Reliability","volume":"46","author":"Goodman","year":"1989","journal-title":"Archives of General Psychiatry"},{"issue":"12","key":"10.1002\/14651858.CD009043.pub2-BIB26|cit26","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1517\/14656566.3.12.1773","article-title":"Aripiprazole: profile on efficacy and safety","volume":"3","author":"Goodnick","year":"2002","journal-title":"Expert Opinion on Pharmacotherapy"},{"key":"10.1002\/14651858.CD009043.pub2-BIB27|cit27","volume-title":"Early Clinical Drug Evluation Unit (ECDEU) Assessment manual for psychopharmacology. National Institute Mental Health (NIMH publication DHEW)","author":"Guy","year":"1976"},{"key":"10.1002\/14651858.CD009043.pub2-BIB28|cit28","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/9780470712184.ch8","article-title":"Chapter 8: Assessing risk of bias in included studies","volume-title":"Cochrane Handbook for Systematic Reviews of Intervention","author":"Higgins","year":"2008"},{"issue":"1","key":"10.1002\/14651858.CD009043.pub2-BIB29|cit29","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD005040.pub2","article-title":"Risperidone for autism spectrum disorder","author":"Jesner","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD009043.pub2-BIB30|cit30","first-page":"217","article-title":"Autistic disturbances of affective contact","volume":"2","author":"Kanner","year":"1943","journal-title":"Nervous Child"},{"issue":"5","key":"10.1002\/14651858.CD009043.pub2-BIB31|cit31","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1542\/peds.2009-1522","article-title":"Prevalence of parent-reported diagnosis of autism spectrum disorders among children in the US, 2007","volume":"124","author":"Kogan","year":"2009","journal-title":"Pediatrics"},{"issue":"4","key":"10.1002\/14651858.CD009043.pub2-BIB32|cit32","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD006569.pub3","article-title":"Aripiprazole versus other atypical antipsychotics for schizophrenia","author":"Komossa","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD009043.pub2-BIB33|cit33","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1007\/s10803-006-0147-5","article-title":"Behavioral and emotional problems in young people with pervasive developmental disorders: relative prevalence, effects of subject characteristics, and empirical classification","volume":"36","author":"Lecavalier","year":"2006","journal-title":"Journal of Autism and Developmental Disorders"},{"issue":"5","key":"10.1002\/14651858.CD009043.pub2-BIB34|cit34","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/BF02172145","article-title":"Autism Diagnostic Interview-Revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders","volume":"24","author":"Lord","year":"1994","journal-title":"Journal of Autism and Developmental Disorders"},{"issue":"3","key":"10.1002\/14651858.CD009043.pub2-BIB35|cit35","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1023\/A:1005592401947","article-title":"The autism diagnostic observation schedule-generic: a standard measure of social and communication deficits associated with the spectrum of autism","volume":"30","author":"Lord","year":"2000","journal-title":"Journal of Autism and Developmental Disorders"},{"issue":"5","key":"10.1002\/14651858.CD009043.pub2-BIB36|cit36","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1542\/peds.2007-2362","article-title":"Management of children with autism spectrum disorders","volume":"120","author":"Myers","year":"2007","journal-title":"Pediatrics"},{"issue":"1","key":"10.1002\/14651858.CD009043.pub2-BIB37|cit37","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1172\/JCI32483","article-title":"Antipsychotics in the treatment of autism","volume":"118","author":"Posey","year":"2008","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1002\/14651858.CD009043.pub2-BIB38|cit38","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager 2011"},{"issue":"6","key":"10.1002\/14651858.CD009043.pub2-BIB39|cit39","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1097\/00004583-199706000-00023","article-title":"Children's Yale-Brown Obsessive Compulsive Scale: Reliability and Validity","volume":"36","author":"Scahill","journal-title":"Journal of the American Academy of Child and Adolescent Psychiatry"},{"key":"10.1002\/14651858.CD009043.pub2-BIB40|cit40","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1038\/sj.npp.1300203","article-title":"Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology","volume":"28","author":"Shapiro","year":"2003","journal-title":"Neuropsychopharmacology"},{"issue":"8","key":"10.1002\/14651858.CD009043.pub2-BIB41|cit41","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1097\/CHI.0b013e318179964f","article-title":"Psychiatric disorders in children with autism spectrum disorders: prevalence, comorbidity and associated factors in a population derived sample","volume":"47","author":"Simonoff","year":"2008","journal-title":"Journal of the American Academy of Child and Adolescent Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD009043.pub2-BIB42|cit42","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1089\/cap.2008.093","article-title":"Aripirazole in pervasive development disorder not otherwise specified and Asperger's disorder: a 14-week, prospective, open-label study","volume":"19","author":"Stigler","year":"2009","journal-title":"Journal of Child and Adolescent Psychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD009043.pub2-BIB43|cit43","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1136\/adc.2004.062083","article-title":"Systematic review of prevalence studies of autism spectrum disorders","volume":"91","author":"Williams","year":"2006","journal-title":"Archives of Diseases in Childhood"},{"key":"10.1002\/14651858.CD009043.pub2-BIB44|cit44","volume-title":"International Statistical Classification of Diseases and Related Health Problems, 10th Revision","volume":"1-3","year":"1994"}],"updated-by":[{"DOI":"10.1002\/14651858.cd009043.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2016,6,26]],"date-time":"2016-06-26T00:00:00Z","timestamp":1466899200000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD009043.pub2\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T22:27:07Z","timestamp":1628548027000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD009043.pub2"}},"subtitle":[],"editor":[{"given":"Tamara","family":"Pringsheim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2012,5,16]]},"references-count":44,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd009043.pub2","relation":{"new_version":[{"id-type":"doi","id":"10.1002\/14651858.CD009043.pub3","asserted-by":"object"}]},"subject":[],"published":{"date-parts":[[2012,5,16]]}}}